Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q2 2024 Earnings Conference Call August 13, 2024 8:30 AM ET Company Participants Jim Caruso – President and Chief Executive Officer Andrei Shustov – Senior Vice President-Medical Jarrod Longcor – Chief Operating Officer Shane Lea – Chief Commercial Officer Chad Kolean – Chief Financial Officer Conference Call Participants Jonathan Aschoff – ROTH Jeff Jones – Oppenheimer Ted Tenthoff – Piper Sandler Operator Good morning, and welcome to Cellectar Biosciences Second Q ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 Cellectar Biosciences, Inc. (Exact name of Registrant as Specified in its Charter) Delaware (State or other jurisdiction of incorporation) | --- | --- | --- | |-------|-------------|-------| | | | | | | | | | | | | | | | | | | | | | | 1-36598 | | | | | | | | (Commission | | | | ...

FLORHAM PARK, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced financial results for the quarter ended June 30, 2024, and provided a corporate update. "With our recent positive data announcement from the CLOVER WaM pivotal study evaluating iopofosine I 131 in Waldenstrom's macroglobulinemia, we remain focused on ...

FLORHAM PARK, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that the company will provide a corporate update for the three months ended June 30, 2024, on Tuesday, August 13, 2024. Management will also host a conference call with investors to discuss financial results and provide an overview at 8:30 am Eastern ...

Cellectar Biosciences, Inc. (NASDAQ:CLRB) KOL and Analyst Day Call July 24, 2024 8:00 AM ET Company Participants James Caruso - President and Chief Executive Officer Sikander Ailawadhi - Professor of Medicine at Mayo Clinic Michael Morris - Co-Founder of United Theranostics and the Medical Director of Advanced Molecular Imaging and Therapy and United Theranostic Centers of Excellence Jarrod Longcor - Chief Operating Officer Conference Call Participants Edward Tenthoff - Piper Sandler Jeff Jones - Oppenheim ...

FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131, a potential first-in-class, targeted radiotherapeutic candidate for the treatment of relapsed/refractory Waldenstrom's macroglobulinemia (WM) patients that received at leas ...

56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40% dual-class refractory (BTKi and rituximab) FLORHAM PARK, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerci ...

Core Viewpoint - Cellectar Biosciences, Inc. has announced the issuance of new warrants that could generate significant gross proceeds, which will support the commercialization of its lead asset, iopofosine I 131, for cancer treatment [1][2][7]. Group 1: New Warrants and Financial Proceeds - The new warrants consist of Tranche A, B, and C, with potential gross proceeds of approximately $73.3 million if fully exercised [1][7]. - Tranche A warrants can generate up to $17.0 million at an exercise price of $2.52, triggered by the FDA's assignment of a review date for iopofosine I 131 [1]. - Tranche B warrants can yield approximately $32.9 million at an exercise price of $4.00, triggered by FDA approval of iopofosine I 131 [1]. - Tranche C warrants can provide about $23.5 million at an exercise price of $5.50, triggered by domestic quarterly revenue from iopofosine I 131 exceeding $10.0 million [1]. - The exercised Tranche B warrants and newly purchased warrants will generate gross proceeds of approximately $19.4 million [7]. Group 2: Product Pipeline and Development Plans - Cellectar is focused on the development of iopofosine I 131, a small-molecule PDC designed for targeted delivery of iodine-131 for cancer treatment [3][10]. - The company plans to file a New Drug Application (NDA) for iopofosine I 131 for the treatment of Waldenstrom's macroglobulinemia in Q4 2024, seeking priority review [2].

Group 1 - Cellectar Biosciences, Inc. has announced the exercise of the majority of Tranche B warrants for Series E preferred stock, generating gross proceeds of approximately $19.4 million, with potential additional proceeds of up to $73.3 million from newly purchased warrants [1][2][11] - The company plans to file a New Drug Application (NDA) for iopofosine I 131 for the treatment of Waldenstrom's macroglobulinemia in Q4 2024, seeking priority review [2] - Cellectar focuses on the development of proprietary drugs for cancer treatment using its Phospholipid Drug Conjugate™ (PDC) delivery platform, aiming for improved efficacy and safety [3][13] Group 2 - The new warrants include Tranche A, B, and C, with Tranche A potentially generating approximately $17.0 million, Tranche B approximately $32.9 million, and Tranche C approximately $23.5 million based on specific exercise triggers [11] - The company's product pipeline features lead asset iopofosine I 131, designed for targeted delivery of iodine-131, along with other preclinical PDC chemotherapeutic programs and partnered assets [13]

The event will feature both company leadership and key investigators, who will discuss the CLOVER WaM study (NCT02952508) and full results. Details are as follows: A replay of the conference call will be available on the Events section of the company's investor relations website. Waldenstrom's macroglobulinemia is a B-cell malignancy characterized by bone marrow infiltration of clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. T ...